M&A - FWHC HOLDINGS, LLC

Add to your watchlist
Back to List of Mergers and Acquisitions

Form Type: SCHEDULE 13D/A

Filing Date: 2025-02-06

Corporate Action: Acquisition

Type: Update

Accession Number: 000119380525000123

Filing Summary: Amendment No. 7 to Statement on Schedule 13D reflects the sale on December 13, 2024, of all shares of Common Stock and securities exchangeable or exercisable for, or convertible into, shares of Common Stock of Innoveren Scientific, Inc. (f/k/a H-Cyte, Inc.) by the Reporting Persons, which include FWHC Holdings, LLC, HOA Capital, LLC, and J. Rex Farrior, III, among others. Post-sale, the Reporting Persons do not beneficially own any Common Stock, representing 0.00% of the outstanding shares. The amendment includes details on the previously beneficially owned securities sold, including shares of Common Stock, Series A Preferred Stock, and warrants. Notably, the amendment states that due to the complexities and volume of the Sale, per share sale pricing cannot be easily determined.

Additional details:

Reporting Person: FWHC Holdings, LLC

Sole Voting Power: 0

Sole Power Of Disposition: 0

Shared Voting Power: 0

Shared Power Of Disposition: 0


Reporting Person: HOA Capital LLC

Sole Voting Power: 0

Sole Power Of Disposition: 0

Shared Voting Power: 0

Shared Power Of Disposition: 0


Reporting Person: J. Rex Farrior

Sole Voting Power: 0

Sole Power Of Disposition: 0

Shared Voting Power: 0

Shared Power Of Disposition: 0


Reporting Person: FWHC Bridge, LLC

Sole Voting Power: 0

Sole Power Of Disposition: 0

Shared Voting Power: 0

Shared Power Of Disposition: 0


Reporting Person: Todd R. Wagner

Sole Voting Power: 0

Sole Power Of Disposition: 0

Shared Voting Power: 0

Shared Power Of Disposition: 0


Reporting Person: FWHC Bridge Friends, LLC

Sole Voting Power: 0

Sole Power Of Disposition: 0

Shared Voting Power: 0

Shared Power Of Disposition: 0


Common Stock Sold: 15,519

Series A Preferred Stock Sold: 33,678,551

Warrants Sold: 224,262

Exercise Price: $14.00


Comments

No comments yet. Be the first to comment!